Schaper Benz & Wise Investment Counsel Inc. WI Boosts Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Schaper Benz & Wise Investment Counsel Inc. WI increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 8.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,502 shares of the company's stock after acquiring an additional 3,400 shares during the period. IDEXX Laboratories makes up approximately 1.5% of Schaper Benz & Wise Investment Counsel Inc. WI's investment portfolio, making the stock its 24th biggest position. Schaper Benz & Wise Investment Counsel Inc. WI owned 0.05% of IDEXX Laboratories worth $18,399,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Amundi boosted its position in shares of IDEXX Laboratories by 8.1% during the fourth quarter. Amundi now owns 758,669 shares of the company's stock valued at $328,018,000 after buying an additional 56,837 shares during the period. Rialto Wealth Management LLC purchased a new position in shares of IDEXX Laboratories during the fourth quarter valued at approximately $30,000. PNC Financial Services Group Inc. boosted its position in shares of IDEXX Laboratories by 4.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 42,012 shares of the company's stock valued at $17,369,000 after buying an additional 1,712 shares during the period. Bank Julius Baer & Co. Ltd Zurich boosted its position in shares of IDEXX Laboratories by 7.5% during the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 223,841 shares of the company's stock valued at $99,130,000 after buying an additional 15,565 shares during the period. Finally, Machina Capital S.A.S. boosted its position in shares of IDEXX Laboratories by 134.4% during the fourth quarter. Machina Capital S.A.S. now owns 3,070 shares of the company's stock valued at $1,269,000 after buying an additional 1,760 shares during the period. Hedge funds and other institutional investors own 87.84% of the company's stock.

Remove Ads

Insider Buying and Selling

In other news, EVP George Fennell sold 9,986 shares of the company's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the company's stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by insiders.

IDEXX Laboratories Stock Up 0.3 %

NASDAQ:IDXX traded up $1.09 during trading hours on Friday, reaching $430.12. The company's stock had a trading volume of 654,250 shares, compared to its average volume of 542,991. The company has a market capitalization of $34.98 billion, a P/E ratio of 40.31, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $562.25. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The stock has a 50 day moving average price of $437.37 and a two-hundred day moving average price of $449.09.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on IDXX. Barclays boosted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Piper Sandler boosted their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a report on Monday, February 10th. Morgan Stanley lowered their price target on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Bank of America boosted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. Finally, Leerink Partnrs upgraded IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.